Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5381-5389

  Ruf, Wolfram ^a   Seftor, Elisabeth A ^b   Petrovan, Ramona J ^a   Weiss, Robert M ^b   Gruman, Lynn M ^b   Margaryan, Naira V ^b   Seftor, Richard E B ^b   Miyagi, Yohei ^c   Hendrix, Mary J C ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; PLACENTA PROTEIN 5; PLASMIN; PROCOAGULANT; PROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOPPLER FLOWMETRY; ENDOTHELIUM CELL; ENZYME REPRESSION; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MELANOMA CELL; PERFUSION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR CELL;

ANIMALS; CHO CELLS; CRICETINAE; GLYCOPROTEINS; HUMANS; LIPOPROTEINS; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; THROMBOPLASTIN; TRANSPLANTATION, HETEROLOGOUS; UVEAL NEOPLASMS;

EID: 0141705426     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Seftor, E. A., Meltzer, P. S., Schatteman, G. C., Gruman, L. M., Hess, A. R., Kirschmann, D. A., Seftor, R. E., and Hendrix, M. J. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit. Rev. Oncol. Hematol., 44: 17-27, 2002.
2. Seftor, E. A., Meltzer, P. S., Kirschmann, D. A., Pe'er, J., Maniotis, A. J., Trent, J. M., Folberg, R., and Hendrix, M. J. Molecular determinants of human uveal melanoma invasion and metastasis. Clin. Exp. Metastasis, 19: 233-246, 2002.
3. Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Leuders, J., Glatfelter, A., Pollack, P., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., Sondak, V., Hayward, N., and Trent, J. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (Lond.), 406: 536-540, 2000.
4. Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Meltzer, P. S., and Hendrix, M. J. C. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol., 155: 739-752, 1999.
5. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., and Seftor, R. E. B. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer, 3: 411-421, 2003.
6. Folberg, R., Hendrix, M. J. C., and Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol., 156: 361-381, 2000.
7. Seftor, R. E. B., Seftor, E. A., Koshikawa, N., Meltzer, P. S., Gardner, L. M. G., Bilban, M., Stetler-Stevenson, W. G., Quaranta, V., and Hendrix, M. J. C. Cooperative interactions of laminin 5 γ2 chain, matrix metallinoproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res., 61: 6322-6327, 2001.
8. Hess, A. R., Seftor, E. A., Gardner, L. M. G., Carles-Kinch, K., Schneider, G. B., Seftor, R. E. B., Kinch, M. S., and Hendrix, M. J. C. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res., 61: 3250-3255, 2001.
9. Hendrix, M. J. C., Seftor, E. A., Meltzer, P. S., Gardner, L. M. G., Hess, A. R., Kirschmann, D. A., Schatteman, G. C., and Seftor, R. E. B. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl. Acad. Sci. USA, 98: 8018-8023, 2001.
10. Hynes, R. O., Bader, B. L., and Hodivala-Dilke, K. Integrins in vascular development. Braz. J. Med. Biol. Res., 32: 501-510, 1999.
11. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6: 389-395, 2000.
12. Risau, W. Mechanisms of angiogenesis. Nature (Lond.), 386: 671-674, 1997.
13. Ruf, W., and Edgington, T. S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J., 8: 385-390, 1994.
14. Ruf, W., and Dickinson, C. D. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc. Med., 8: 350-356, 1998.
15. Riewald, M., and Ruf, W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc. Med., 12: 149-154, 2002.
16. Huang, Z-F., Higuchi, D., Lasky, N., and Broze, G. J., Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood, 90: 944-951, 1997.
17. Mast, A. E., Higuchi, D. A., Huang, Z. F., Warshawsky, I., Schwartz, A. L., and Broze, G. J., Jr. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem. J., 327: 577-583, 1997.
18. Lupu, C., Goodwin, C. A., Westmuckett, A. D., Emeis, J. J., Scully, M. F., Kakkar, V. V., and Lupu, F. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler. Thromb. Vasc. Biol., 17: 2964-2974, 1997.
19. Sevinsky, J. R., Rao, L. V. M., and Ruf, W. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J. Cell Biol., 133: 293-304, 1996.
20. Mueller, B. M., and Ruf, W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis. J. Clin. Investig., 101: 1372-1378, 1998.
21. Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., Van Vlaenderen, I., Demunck, H., Kasper, M., Breier, G., Evrard, P., Müller, M., Risau, W., Edgington, T., and Collen, D. Role of tissue factor in embryonic blood vessel development. Nature (Lond.), 383: 73-75, 1996.
22. Contrino, J., Hair, G., Kreutzer, D. L., and Rickles, F. R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat. Med., 2: 209-215, 1996.
23. Sprecher, C. A., Kisiel, W., Mathewes, S., and Foster, D. C. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc. Natl. Acad. Sci. USA, 91: 3353-3357, 1994.
24. Miyagi, Y., Koshikawa, N., Yasumitsu, H., Miyagi, E., Hirahara, F., Aoki, I., Misugi, K., Umeda, M., and Miyazaki, K. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J. Biochem. (Tokyo), 116: 939-942, 1994.
25. r 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch. Biochem. Biophys., 335: 82-92, 1996.
26. Liu, Y. Y., Stack, S. M., Lakka, S. S., Khan, A. J., Woodley, D. T., Rao, J. S., and Rao, C. N. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch. Biochem. Biophys., 370: 112-118, 1999.
27. Petersen, L. C., Sprecher, C. A., Foster, D. C., Blumberg, H., Hamamoto, T., and Kisiel, W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry, 35: 266-272, 1996.
28. Herman, M., Sukhova, G. K., Kisiel, W., Foster, D., Kehry, M., Libby, P., and Schonbeck, U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Investig., 107: 1117-1126, 2001.
29. Izumi, H., Takahashi, C., Oh, J., and Noda, M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett., 481: 31-36, 2000.
30. Jin, M., Udagawa, K., Miyagi, E., Nakazawa, T., Hirahara, F., Yasumitsu, H., Miyazaki, K., Nagashima, Y., Aoki, I., and Miyagi, Y. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol. Oncol., 83: 325-333, 2001.
31. Konduri, S. D., Tasiou, A., Chandrasekar, N., Nicolson, G. L., and Rao, J. S. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin. Exp. Metastasis, 18: 303-308, 2000.
32. Rao, C. N., Reddy, P., Reeder, D. J., Liu, Y., Stack, S. M., Kisiel, W., and Woodley, D. T. Prokaryotic expression, purification, and reconstitution of biological activities (antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. Biochem. Biophys. Res. Commun., 276: 1286-1294, 2000.
33. Neaud, V., Hisaka, T., Monvoisin, A., Bedin, C., Balabaud, C., Foster, D., Desmouliere, A., Kisiel, W., and Rosenbaum, J. Paradoxical pro-invasivc effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J. Biol. Chem., 275: 35565-35569, 2000.
34. Blindt, R., Vogt, F., Lamby, D., Zeiffer, U., Krott, N., Hilger-Eversheim, K., Hanrath, P. vom, D. J., and Bosserhoff, A. K. Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells. J. Vasc. Res., 39: 340-352, 2002.
35. Iino, M., Foster, D. C., and Kisiel, W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler. Thromb. Vasc. Biol., 18: 40-46, 1998.
36. Clarijs, R., Otte-Holler, I., Ruiter, D. J., and de Waal, R. M. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Investig. Ophthalmol. Vis. Sci., 43: 912-918, 2002.
37. Maniotis, A. J., Chen, X., Garcia, C., DeChristopher, P. J., Wu, D., Pe'er, J., and Folberg, R. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Investig., 82: 1031-1043, 2002.
38. Liu, C., Huang, H., Donate, F., Dickinson, C., Santucci, R., El Sheikh, A., Vessella, R., and Edgington, T. S. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res., 62: 5470-5475, 2002.
39. Shirakawa, K., Kobayashi, H., Heike, Y., Kawamoto, S., Brechbiel, M. W., Kasumi, F., Iwanagi, T., Konishi, F., Terada, M., and Wakasugi, H. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res., 62: 560-566, 2002.
40. 256. Cancer Res., 62: 860-866, 2002.
41. 290 is required for efficient activation of the macromolecular substrate factor X. Biochemistry, 33: 11631-11636, 1994.
42. Dickinson, C. D., and Ruf, W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J. Biol. Chem., 272: 19875-19879, 1997.
43. Fischer, E. G., Riewald, M., Huang, H. Y., Miyagi, Y., Kubota, Y., Mueller, B. M., and Ruf, W. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J. Clin. Investig., 104: 1213-1221, 1999.
44. Ott, I., Miyagi, Y., Miyazaki, K., Heeb, M. J., Mueller, B. M., Rao, L. V. M., and Ruf, W. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler. Thromb. Vasc. Biol., 20: 874-882, 2000.
45. Ruf, W., and Edgington, T. S. An anti-tissue factor monoclonal antibody which inhibits TF: VIIa complex is a potent anticoagulant in plasma. Thromb. Haemost., 66: 529-533, 1991.
46. Ruf, W., Rehemtulla, A., and Edgington, T. S. Antibody mapping of tissue factor implicates two different exon-encoded regions in function. Biochem. J., 278: 729-733, 1991.
47. Wun, T-C., Kretzmer, K. K., Girard, T. J., Miletich, J. P., and Broze, G. J. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J. Biol. Chem., 263: 6001-6004, 1988.
48. Stone, M. J., Ruf, W., Miles, D. J., Edgington, T. S., and Wright, P. E. Recombinant soluble human tissue factor secreted by Saccaromyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity, and physical characterization. Biochem. J., 310: 605-614, 1995.
49. Shoji, M., Hancock, W. W., Abe, K., Micko, C., Casper, K. A., Baine, R. M., Wilcox, J. N., Danave, I., Dillehay, D. L., Matthews, E., Contrino, J., Morrissey, J. H., Gordon, S., Edgington, T. S., Kudryk, B., Kreutzer, D. L., and Rickles, F. R. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am. J. Pathol., 152: 399-411, 1998.
50. 24→Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2). Thromb. Res., 94: 147-152, 1999.
51. Bell, S. E., Mavila, A., Salazar, R., Bayless, K. J., Kanagala, S., Maxwell, S. A., and Davis, G. E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci., 114: 2755-2773, 2001.
52. Seftor, R. E., Seftor, E. A., Kirschmann, D. A., and Hendrix, M. J. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 [γ]2 chain promigratory fragments and vasculogenic mimicry. Mol. Cancer Ther., 1: 1173-1179, 2002.
53. Shirakawa, K., Tsuda, H., Heike, Y., Kato, K., Asada, R., Inomata, M., Sasaki, H., Kasumi, F., Yoshimoto, M., Iwanaga, T., Konishi, F., Terada, M., and Wakasugi, H. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res., 61: 445-451, 2001.
54. Pezzella, F. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet, 355: 1787-1788, 2000.
55. Sood, A. K., Seftor, E. A., Fletcher, M. S., Gardner, L. M. G., Heidger, P. M., Buller, R. E., Seftor, R. E. B., and Hendrix, M. J. C. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol., 158: 1279-1288, 2001.
56. Sharma, N., Seftor, R. E. B., Seftor, E. A., Gruman, L. M., Heidger, P. M., Jr., Cohen, M. B., Lubaroff, D. M., and Hendrix, M. J. C. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate, 50: 189-201, 2002.
57. Passalidou, E., Trivella, M., Singh, N., Ferguson, M., Hu, J., Cesario, A., Grinone, P., Nicholson, A. G., Goldstraw, P., Ratcliffe, C., Tetlow, M., Leigh, I., Harris, A. L., Gatter, K. C., and Pezzella, F. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br. J. Cancer, 86: 244-249, 2002.
58. Ruf, W., and Mueller, B. M. Tissue factor in cancer angiogenesis and metastasis. Curr. Opin. Hematol., 3: 379-384, 1996.
59. Shinoda, E., Yui, Y., Hattori, R., Tanaka, M., Inoue, R., Aoyama, T., Takimoto, Y., Mitsui, Y., Miyahara, K., Shizuta, Y., and Sasayama, S. Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells. J. Biol. Chem., 274: 5379-5384, 1999.
60. Potgens, A. J., van Altena, M. C., Lubsen, N. H., Ruiter, D. J., and de Waal, R. M. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am. J. Pathol., 148: 1203-1217, 1996.
61. Hendrix, M. J. C., Seftor, E. A., Meltzer, P. S., Hess, A. R., Gruman, L. M., Nickoloff, B. J., Miele, L., Sheriff, D. D., Schatteman, G. C., Bourdon, M. A., and Seftor, R. E. B. The plasticity of aggressive melanoma tumor cells: recapitulation of an embryonic stem cell program. Rec. Adv. Res. Updates, 3: 191-200, 2002.